Pnc Financial Services Group, Inc. Viridian Therapeutics, Inc.\De Transaction History
Pnc Financial Services Group, Inc.
- $156 Billion
- Q3 2024
A detailed history of Pnc Financial Services Group, Inc. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 75 shares of VRDN stock, worth $1,447. This represents 0.0% of its overall portfolio holdings.
Number of Shares
75
Previous 33
127.27%
Holding current value
$1,447
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding VRDN
# of Institutions
182Shares Held
76.9MCall Options Held
581KPut Options Held
439K-
Black Rock Inc. New York, NY4.77MShares$92.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$85.3 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$74.9 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$72.4 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$66.5 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $770M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...